FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions is based on detecting eNOS activity modulation mechanisms and refers to a method for screening for endothelial NO-synthase (eNOS) modulator expression, a diagnostic technique for a cardiovascular disease in an individual, using NEUR1 for identifying a drug for preventing and/or treating a disease related to eNOS dysfunction, particularly the cardiovascular disease, using NEUR1 for detecting a signal transmission component in eNOS expression and using NEUR1 for eNOS promoter activity regulation.
EFFECT: group of inventions is effective in treating and preventing the diseases related to eNOS dysfunction.
25 cl, 6 dwg, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL EUKARYOTIC CELLS AND METHODS FOR PREPARING THEREOF FOR RECOMBINANT EXPRESSION OF PRODUCT OF INTEREST | 2014 |
|
RU2712507C2 |
| APPLICATION OF PAK INHIBITOR FOR ARTHROPATHY TREATMENT | 2004 |
|
RU2360696C2 |
| ANTIBODIES AGAINST ANGPTL3/8 COMPLEX AND METHODS OF THEIR USE | 2019 |
|
RU2799796C2 |
| TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF | 2013 |
|
RU2661104C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| COMPOUNDS FOR REMYELINATION BLOCKADE TREATMENT IN DISEASES RELATED TO EXPRESSION OF HERV-W SHELL PROTEIN | 2013 |
|
RU2636355C2 |
| RECOMBINANT DNA ELEMENTS FOR RECOMBINANT PROTEINS EXPRESSION IN THE HOST CELL | 2012 |
|
RU2619161C2 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
| NOVEL EUKARYOTIC CELLS AND METHODS FOR PREPARING THEM FOR RECOMBINANT EXPRESSION OF A PRODUCT OF INTEREST | 2014 |
|
RU2720525C2 |
